These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 27870945)

  • 21. Erythropoiesis in myelodysplastic syndrome: expression of receptors for erythropoietin and kit ligand.
    Backx B; Broeders L; Hoefsloot LH; Wognum B; Löwenberg B
    Leukemia; 1996 Mar; 10(3):466-72. PubMed ID: 8642863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recombinant human erythropoietin in combined treatment with granulocyte- or granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes.
    Kasper C; Zahner J; Sayer HG
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):497-502. PubMed ID: 12242514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of qinghuang power combined Chinese herbs for shen reinforcing and Pi strengthening on activated T cells of myelodysplastic syndrome patients].
    Gao F; Ma R; Yang XH; Xu YG
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Apr; 33(4):443-7. PubMed ID: 23841258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro deprivation of CD8(+)CD57(+)T cells promotes the malignant growth of bone marrow colony cells in patients with lower-risk myelodysplastic syndrome.
    Zheng Z; Qianqiao Z; Qi H; Feng X; Chunkang C; Xiao L
    Exp Hematol; 2010 Aug; 38(8):677-84. PubMed ID: 20394797
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant human erythropoietin treatment of chronic renal failure patients normalizes altered phenotype and proliferation of CD4-positive T lymphocytes.
    Lisowska KA; Debska-Slizien A; Radzka M; Witkowski JM; Rutkowski B; Bryl E
    Artif Organs; 2010 Mar; 34(3):E77-84. PubMed ID: 20447038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interleukin-17 enhances the production of interferon-γ and tumour necrosis factor-α by bone marrow T lymphocytes from patients with lower risk myelodysplastic syndromes.
    Zhang Z; Li X; Guo J; Xu F; He Q; Zhao Y; Yang Y; Gu S; Zhang Y; Wu L; Chang C
    Eur J Haematol; 2013 May; 90(5):375-84. PubMed ID: 23331180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of IL-7 and IL-15 on T cell phenotype in myelodysplastic syndromes.
    Dong W; Ding T; Wu L; Ren X; Epling-Burnette PK; Yang L
    Oncotarget; 2016 May; 7(19):27479-88. PubMed ID: 27036031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Poor response to recombinant erythropoietin is associated with loss of T-lymphocyte CD28 expression and altered interleukin-10 production.
    Cooper AC; Breen CP; Vyas B; Ochola J; Kemeny DM; Macdougall IC
    Nephrol Dial Transplant; 2003 Jan; 18(1):133-40. PubMed ID: 12480971
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Analysis of T cell subsets and CD3zeta chain expression in myelodysplastic syndrome patients].
    Xu F; Liu T; Zhu HL; Cui X; Xu CG; Mao YQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Dec; 12(6):779-82. PubMed ID: 15631660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant human erythropoietin in very elderly patients with myelodysplastic syndromes: results from a retrospective study.
    Tatarelli C; Piccioni AL; Maurillo L; Naso V; Battistini R; D'Andrea M; Criscuolo M; Nobile C; Villivà N; Mancini S; Neri B; Breccia M; Fenu S; Buccisano F; Voso MT; Latagliata R; Aloe Spiriti MA
    Ann Hematol; 2014 Aug; 93(8):1413-20. PubMed ID: 24647684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular and flow cytometric characterization of the CD4 and CD8 T-cell repertoire in patients with myelodysplastic syndrome.
    Melenhorst JJ; Eniafe R; Follmann D; Nakamura R; Kirby M; Barrett AJ
    Br J Haematol; 2002 Oct; 119(1):97-105. PubMed ID: 12358908
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circadian rhythm of serum erythropoietin in myelodysplastic syndromes.
    Pasqualetti P; Collacciani A; Casale R
    Eur Rev Med Pharmacol Sci; 2000; 4(5-6):111-5. PubMed ID: 11710507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant human erythropoietin (rHuEPO) for treatment of myelodysplastic syndrome.
    Zeigler ZR; Jones D; Rosenfeld CS; Shadduck RK
    Stem Cells; 1993 Jan; 11(1):49-55. PubMed ID: 8457781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A study on early activation of T lymphocytes and soluble tumor necrosis factor receptor in patients with myelodysplastic syndrome].
    Shen R; Xu CG; Li LZ; Zhang T; Qin XM; Li J
    Zhonghua Nei Ke Za Zhi; 2003 Dec; 42(12):857-60. PubMed ID: 14728878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Erythropoietin as an independent prognostic factor in myelodysplastic syndromes.
    Boyko O; Simonova M; Knysh N; Danysh O; Vygovska Y; Masliak Z
    Exp Oncol; 2021 Mar; 43(1):41-45. PubMed ID: 33785713
    [TBL] [Abstract][Full Text] [Related]  

  • 36. IL10 inversely correlates with the percentage of CD8⁺ cells in MDS patients.
    Lopes MR; Traina F; Campos Pde M; Pereira JK; Machado-Neto JA; Machado Hda C; Gilli SC; Saad ST; Favaro P
    Leuk Res; 2013 May; 37(5):541-6. PubMed ID: 23453286
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential effect of sodium arsenite during the activation of human CD4+ and CD8+ T lymphocytes.
    Tenorio EP; Saavedra R
    Int Immunopharmacol; 2005 Dec; 5(13-14):1853-69. PubMed ID: 16275621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes.
    Stasi R; Brunetti M; Terzoli E; Amadori S
    Blood; 2002 Mar; 99(5):1578-84. PubMed ID: 11861271
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Azacitidine differentially affects CD4(pos) T-cell polarization in vitro and in vivo in high risk myelodysplastic syndromes.
    Bontkes HJ; Ruben JM; Alhan C; Westers TM; Ossenkoppele GJ; van de Loosdrecht AA
    Leuk Res; 2012 Jul; 36(7):921-30. PubMed ID: 22503132
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes.
    Musto P; Modoni S; Alicino G; Savino A; Longo A; Bodenizza C; Falcone A; D'Arena G; Scalzulli P; Perla G
    Haematologica; 1994; 79(6):493-9. PubMed ID: 7896207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.